Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial published : Previous years save search
Health Canada Approves KEYTRUDA as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma
Published: 2024-04-19 (Crawled : 13:00) - biospace.com/
MRK | $125.12 -0.09% 1.6M
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: 0.0%
health treatment for canada advanced keytruda
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
Published: 2024-04-19 (Crawled : 11:00) - globenewswire.com
OCGN | News A | $1.295 -1.89% 1.8M
|
Health Technology
|
| O: -15.41%
H: 0.0%
C: 0.0%
ocu410 armada trial therapy
Clinical Trials Matching Software Market Projected to Reach $832.56 million by 2030 - Exclusive Report by 360iResearch
Published: 2024-04-19 (Crawled : 04:00) - prnewswire.com
IBM | $182.05 0.32% 640K
|
Technology Services
|
| O: -0.17%
H: 0.0%
C: 0.0%
report million software reach trials market
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
YS | News | $0.8002 -6.41% 140K
|
n/a
|
| O: -7.45%
H: 0.0%
C: 0.0%
hepatitis vaccine license granted biopharma virus trial
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
ABBV | News | $164.91 0.15% 1.2M
|
Health Technology
|
| O: 0.75%
H: 0.0%
C: 0.0%
rinvoq positive cell results study
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
CALT | News | $17.65 1.2K
|
Health Technology
|
| O: -0.87%
H: 3.58%
C: -2.86%
nephropathy congress world nefecon trial therapeutics
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
BNTC | News | $6.825 0.07% 110K
|
Health Technology
|
| O: 5.41%
H: 41.06%
C: 29.66%
bb-301 first positive biopharma for trial opmd study
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
CERE | News | $42.15 0.02% 110K
|
Finance
|
| O: 0.78%
H: 0.0%
C: 0.0%
disease positive for topline parkinson’s trial therapeutics results living
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
BPTH | News 0 d | $4.11 -2.14% 1.5M
|
Health Technology
|
| O: 72.84%
H: 41.77%
C: -22.37%
bp1002 leukemia trial
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
Published: 2024-04-17 (Crawled : 22:00) - biospace.com/
EOLS | $11.4 -1.38% 38K
|
Health Technology
|
| O: -1.49%
H: 0.0%
C: 0.0%
jeuveau publication for study
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
Published: 2024-04-17 (Crawled : 22:00) - biospace.com/
DMAC | $2.49 1.5K
|
Health Technology
|
| O: 4.43%
H: 0.0%
C: 0.0%
dm199 first stroke treatment for trial therapeutics
Artiva Biotherapeutics Announces First Patient Dosed in Phase 1 Trial of AlloNK® Cell Therapy Candidate in Lupus Nephritis
Published: 2024-04-17 (Crawled : 15:00) - biospace.com/
AFMD | $5.07 7.8K
|
Health Technology
|
| O: -2.42%
H: 0.0%
C: 0.0%
allonk first candidate lupus cell trial therapy
Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor
Published: 2024-04-17 (Crawled : 14:00) - biospace.com/
NVO | $123.43 0.55% 1.4M
|
Health Technology
|
| O: 1.22%
H: 0.21%
C: -0.34%
vent-02 trial therapeutics results
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
IMMP | News | $2.23 1.36% 18K
|
Health Technology
|
| O: -6.87%
H: 0.0%
C: 0.0%
tacti-004 lung positive cancer cell for trial
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
Published: 2024-04-17 (Crawled : 12:00) - prnewswire.com
NRBO | $3.44 14K
|
Health Technology
|
| O: 8.53%
H: 0.0%
C: -6.23%
da-1726 obesity first treatment pharmaceuticals for trial
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
EVAX | $4.2 -0.47% 11K
|
Manufacturing
|
| O: 0.25%
H: 0.0%
C: 0.0%
evx-01 first vaccine cancer trial
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
SAGE | $13.46 3.26% 280K
|
Health Technology
|
| O: -15.02%
H: 3.55%
C: -3.01%
sage-718 disease treatment topline parkinson’s therapeutics results study
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
Published: 2024-04-17 (Crawled : 11:00) - globenewswire.com
CTSO | $0.8066 0.7% 5.1K
|
Health Technology
|
| O: -0.99%
H: 0.0%
C: 0.0%
association presentation for meeting trial results
Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
Published: 2024-04-17 (Crawled : 11:00) - biospace.com/
LLY | $731.1 -1.99% 1M
|
Health Technology
|
| O: 1.03%
H: 1.66%
C: -1.11%
obesity tirzepatide
SyntheticMR and SimonMed Expand Trials of Synthetic MRI Testing and Announce Upcoming Expansion of Synthetic Availability from SyntheticMR's SyMRI NEURO Software at SimonMed Facilities
Published: 2024-04-17 (Crawled : 09:00) - prnewswire.com
PHG | $20.065 0.43% 200K
|
Health Technology
|
| O: -2.01%
H: 1.0%
C: 0.7%
software expansion trials
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
ZCMD | $1.98 36.55% 27M
|
Commercial Services
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
AULT | $0.304 25.57% 47M
|
Manufacturing
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
Your saved searches
Save your searches and get alerts when important news are released.